ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: This is commonly reported after BCR-ABL TKI therapy, especially imatinib and to a lesser extent nilotinib, dasatinib, and bosutinib in CML patients.173 The most common edema locations associated with imatinib are the periorbital space and the lower limbs.208 Increased edema risk is reported in patients 65 years or older, and those with cardiac disease, renal insufficiency, HTN, hypercholesterolemia, and a history of autoimmune diseases.15 Regular monitoring of body weight, heart and lung symptoms, chest imaging, and peripheral tissue tone to detect edema is recommended.